Drug Properties and Optimization

Comprehensive vocabulary flashcards covering drug-target interactions, physicochemical properties, ionization equilibria, biological absorption barriers, Lipinski's Rule of Five, metabolic pathways, and lead optimization strategies.

Electrostatic Interactions (Drug Binding)

Relatively strong, non-directional noncovalent interactions between oppositely charged groups whose strength increases when buried inside a hydrophobic or lipophilic pocket away from water.

Hydrogen-Bond Donor (HBD)

A functional group containing an appropriate $X\text{--}H$ bond (commonly $O\text{--}H$ or $N\text{--}H$) that supplies the hydrogen atom for a hydrogen bond. Counts are based on donor groups rather than individual hydrogen atoms (e.g., $-\text{NH}_2 = 1\text{ HBD}$).

Hydrogen-Bond Acceptor (HBA)

An atom (commonly oxygen or nitrogen) possessing a suitable available lone pair of electrons to accept a hydrogen bond. Some heteroatoms, such as amide nitrogens, do not act as acceptors ($\text{amide nitrogen} = 0\text{ HBA}$).

Dipole-Dipole Interactions

Moderate-strength noncovalent attractions between polar groups with permanent partial charges ($\delta^+ \cdots \delta^-$), common in groups with strong dipoles like carbonyls, whose strength increases in less polar or hydrophobic environments.

van der Waals (Dispersion) Interactions

Weak, individual noncovalent forces arising from temporary fluctuations in electron distribution between atoms in close contact, increasing in strength with greater surface area contact within a complementary binding pocket.

Desolvation

The energetically costly process of displacing ordered water molecules from a drug and its target binding site during the binding process.

Potency

A measure of the concentration or dose of a drug required to produce a specified biological effect, where a lower concentration or dose indicates greater potency; distinct from maximum efficacy.

Structure-Activity Relationships (SAR)

The systematic process of making structural modifications to an active lead compound, testing biological activity, and analyzing results to determine how structural changes govern potency and target interaction.

Structure-Property Relationships (SPR)

The study and optimization of how chemical structural changes impact physicochemical (solubility, permeability, $\text{p}K_a$, lipophilicity) and biological/pharmacokinetic properties (metabolic stability, protein binding).

High-Throughput Screening (HTS)

An automated, rapid screening method that tests large numbers of compounds against a target, typically using one or a few concentrations, to identify initial hits.

Biochemical Assay

An in vitro test performed using purified targets or isolated biological components (such as purified enzyme activity) outside a living organism.

Passive Membrane Permeability

The passive diffusion of drug molecules across the nonpolar interior of a lipid bilayer (approximately $49\,\text{Å}$ thick), which is favored by the neutral (uncharged) form of an ionizable drug.

$\text{p}K_a$ of a Base

The equilibrium constant value defined for a basic group that specifically refers to the acidity of its protonated conjugate acid form ($\text{BH}^+ \rightleftharpoons \text{B} + \text{H}^+$); bases are predominantly charged when $\text{pH} < \text{p}K_a$ and neutral when $\text{pH} > \text{p}K_a$.

$\text{p}K_a$ of an Acid

The equilibrium constant value defined for the deprotonation of the acidic form of a group ($\text{HA} \rightleftharpoons \text{A}^- + \text{H}^+$); acids are predominantly neutral when $\text{pH} < \text{p}K_a$ and charged when $\text{pH} > \text{p}K_a$.

Aqueous Reference $\text{p}K_a$ Range

The practical thermodynamic boundaries established by water in aqueous solutions, bounded approximately by $\text{H}_3\text{O}^+$ ($\text{p}K_a \approx -1.7$) and $\text{H}_2\text{O}$ ($\text{p}K_a \approx 15.7$).

Amphiprotic Group

A functional group capable of acting either as an acid or as a base depending on the surrounding chemical environment.

Bile Salts

Steroidal surfactants (such as glycocholic acid) present in the small intestine that assemble into micelles to aid fat digestion and solubilize lipophilic drugs.

First-Pass Metabolism

The enzymatic breakdown of orally administered drugs occurring primarily in the liver via portal circulation following absorption from the gastrointestinal tract, reducing systemic drug exposure.

Plasma Protein Binding

The reversible association of circulating drug molecules (particularly lipophilic drugs) with blood plasma proteins, setting up an equilibrium between free (unbound) active drug and protein-bound drug.

ADME

An acronym defining the four primary pharmacokinetic processes governing drug disposition and biological barrier navigation: Absorption, Distribution, Metabolism, and Excretion.

Lipinski's Rule of Five

A guideline stating that poor oral absorption is significantly more likely when a compound violates two or more of four criteria: more than $5$ hydrogen-bond donors, more than $10$ hydrogen-bond acceptors, molecular weight greater than $500\,\text{Da}$, or calculated $\text{LogP} > 5$ (or measured $\text{LogP} > 4.15$).

$$\text{LogP}$$

The logarithm of the octanol/water partition coefficient exclusively for the neutral (non-ionized) form of a compound, representing intrinsic lipophilicity: $\text{LogP} = \log\left(\frac{[\text{Drug}_{\text{octanol}}]}{[\text{Drug}_{\text{water}}]}\right)$.

$$\text{LogD}$$

The distribution coefficient measuring the octanol/water partitioning of both ionized and non-ionized forms of a compound at a specified pH (commonly reported as $\text{LogD}_{7.4}$, with a suggested drug-like range of $1 < \text{LogD}_{7.4} < 3$).

Shake-Flask Method

A standard solution-based method for measuring lipophilicity by equilibrating a drug between immiscible octanol and water phases and measuring the concentration in each phase.

PAMPA (Parallel Artificial Membrane Permeability Assay)

A simple, rapid, high-throughput in vitro permeability assay utilizing an artificial lipid membrane interposed between donor and receiver compartments to evaluate passive membrane permeability.

Caco-2 Assay

A permeability assay utilizing a monolayer of cultured human intestinal-like epithelial cells to measure both passive diffusion and transporter-mediated transcellular and paracellular transport.

Biopharmaceutics Classification System (BCS)

A regulatory classification framework categorizing drug substances into four classes based on their aqueous solubility and intestinal permeability.

BCS Class 1

A class of drugs characterized by high aqueous solubility and high membrane permeability, generally possessing favorable oral absorption and eligible for biowaivers.

BCS Class 2

A class of drugs characterized by low aqueous solubility and high membrane permeability, where dissolution rate and solubility limit oral absorption.

BCS Class 3

A class of drugs characterized by high aqueous solubility and low membrane permeability, where biological barrier crossing limits absorption.

BCS Class 4

A class of drugs characterized by low aqueous solubility and low membrane permeability, presenting significant formulation and bioavailability hurdles.

Phase I Metabolism

Enzymatic metabolic transformations involving oxidation, reduction, or hydrolysis that typically expose or introduce functional groups (such as $\text{--OH}$) into a substrate.

Cytochrome P450 (CYP) Enzymes

A superfamily of heme-containing iron ($\text{Fe}$) enzymes found in the liver and other tissues that catalyze Phase I oxidation reactions utilizing molecular oxygen ($\text{O}_2$) and electrons supplied by NADPH.

Phase II Metabolism

Conjugation reactions (such as glucuronidation, sulfation, acetylation, and glutathione conjugation) that attach polar endogenous molecules to drugs or metabolites to facilitate excretion.

Liver Microsomal Stability

An in vitro metabolic assay utilizing subcellular membrane fractions from liver tissue containing CYP enzymes to assess the enzymatic clearance rate and half-life ($T_{1/2}$) of a drug.

Classical Isosteres

Atoms, ions, or groups of atoms that possess similar electronic valence configurations and comparable steric sizes or bonding characteristics (e.g., exchanging $-\text{OH}$ for $-\text{NH}_2$ or $-\text{CH}_3$).

Non-Classical Isosteres

Bioisosteric replacement groups that differ in overall shape, size, or valence electronic structure compared to the parent group, yet maintain similar biological activity and interactions while improving physicochemical properties.

Chain Extension and Contraction

A lead optimization strategy in which methylene groups or linker atoms are added or removed between binding pharmacophores to optimize distance and orientation relative to binding regions in the target site.

Ring Expansion and Contraction

The modification of ring size in a lead compound to adjust spatial positioning, molecular flexibility, and geometric orientation of target-binding groups (e.g., expansion to a 7-membered ring in cilazaprilat).

Molecular Simplification

The systematic removal of unnecessary stereocenters, bulky frameworks, or excessive ring systems from a natural or lead product (e.g., simplifying cocaine to procaine) to maintain activity while easing synthesis and reducing cost.

Pharmacophore

The specific 3D spatial arrangement of steric and electronic interaction features (hydrogen-bond donors/acceptors, ionic groups, van der Waals regions) essential for optimal binding and biological activity at a target.